Theras, Inc., D/b/a Bbot (bridgebio Oncology Therapeutics)
Clinical trials sponsored by Theras, Inc., D/b/a Bbot (bridgebio Oncology Therapeutics), explained in plain language.
-
New drug targets Cancer's fuel line in first human trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, colorectal, or lung cancer) that have not responded to standard treatments. The drug works by blocking a key cancer growth signal (PI3Kα:RAS). The main goals are to find a safe …
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 16, 2026 23:56 UTC
-
New pill takes on hard-to-treat KRAS cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in adults with advanced lung, pancreatic, or colorectal cancers that have a KRAS mutation. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. About 387 participants w…
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 07, 2026 18:41 UTC
-
New targeted drug enters human testing for hard-to-treat lung cancer
Disease control Recruiting nowThis early-stage study tests a new drug called BBO-8520 in about 350 adults with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The main goals are to check safety and find the right dose, while also seeing if the drug shrinks tumors. Participa…
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 04, 2026 16:23 UTC